Samsung Biologics stock edges higher as tender offer and union talks shape outlook

Samsung Biologics stock (ISIN KR7207940008) gained about 0.13 percent on the Korea Exchange on September 1, 2026, as investors digested a series of strategic and labor developments around the South Korean contract drug manufacturer.

Capital increase sets financial tone

According to an analysis by Asia Business Daily dated August 31, 2026, Samsung Biologics plans to raise roughly 3 trillion South Korean won through a capital increase that involves issuing 2.27 million new common shares at an expected issue price of 1,322,000 won per share.

This planned equity issuance, reported ahead of trading on September 1, 2026, represents a significant expansion of the company’s capital base and signals management’s intent to secure funding for growth projects, potential acquisitions, or capacity investments in its biologics manufacturing network.

Union mediation resumes after historic strike

Per a report by Aju Press on September 1, 2026, Samsung Biologics and its labor union have agreed to resume mediation as early as September 8, 2026, in an attempt to resolve a wage dispute that led to the first strike in the company’s history.

The renewed talks follow a period of labor tension in the South Korean biopharmaceutical sector and are closely watched by shareholders, as labor stability is seen as an important factor for maintaining uninterrupted biologics production and meeting contract manufacturing obligations for global pharmaceutical clients.

Tender offer for PolyPeptide highlights expansion

On September 1, 2026, industry coverage summarized that Samsung Biologics plans to launch a takeover offer for Swiss contract drugmaker PolyPeptide Group, valuing the transaction at around 1.46 billion Swiss francs, or approximately 1.80 billion United States dollars.

Shareholders of PolyPeptide are expected to receive 44.31 Swiss francs per registered share under the offer, according to sector-focused news reports compiled on September 1, 2026, which positions Samsung Biologics to broaden its global footprint in peptide-based therapeutics and strengthen its position in outsourced development and manufacturing services.

Product and business context

Samsung Biologics primarily focuses on contract development and manufacturing of biologic drugs, providing large-scale manufacturing services for monoclonal antibodies and other complex biologics to pharmaceutical and biotech clients worldwide.

Stock price and market context

According to data compiled by a major financial portal on September 1, 2026, Samsung Biologics stock recently traded around 1,518,000 South Korean won, up about 2.15 percent compared with the previous close, while intraday index commentary from Asia Business Daily indicated a modest gain of 0.13 percent for the stock in the broader KOSPI market environment.